33
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Zack Moore, MD, MPH May 20, 2014

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)testyourwell.nc.gov/.../2014/MERS_slides_CD_Conf_2014.pdf · 2016. 11. 21. · MERS-CoV: Clinical • Range of presentations*

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

  • Middle East Respiratory Syndrome Coronavirus

    (MERS-CoV)

    Zack Moore, MD, MPH May 20, 2014

  • Coronaviruses (CoVs)

    • Human CoVs first isolated in the 1960s • Six human CoVs identified to date:

    – HCoV-229E – HCoV-OC43 – HCoV-NL63 – HCoV-HKU1 – SARS-CoV – Middle East Respiratory Syndrome Coronavirus

    (MERS-CoV)

    http://www.bt.cdc.gov/coca/ppt/2013/06_13_13_MERSCoV_FINAL.pdf

  • Non-SARS Human CoVs: Epidemiology

    • Worldwide • Winter and spring in temperate climates • Exposure common in early childhood • Droplet, contact, and indirect contact • Symptoms and viral loads high first few days

    of illness • Incubation period 2–5 days

    http://www.bt.cdc.gov/coca/ppt/2013/06_13_13_MERSCoV_FINAL.pdf

  • Non-SARS Human CoVs: Clinical Spectrum of Illness

    • Most often associated with upper respiratory tract infections in children

    • Pneumonia and lower tract infections in immunocompromised individuals and the elderly

    • May play a role in exacerbations of underlying respiratory diseases

    http://www.bt.cdc.gov/coca/ppt/2013/06_13_13_MERSCoV_FINAL.pdf

  • SARS

    • First recognized Nov, 2002 as sporadic cases in Guandong province, China

    • Outbreak period 2002–2003 • Hong Kong hotel contributed to spread of

    virus to several countries • 8,098 probable SARS cases

    – 774 deaths (10%)

    http://www.bt.cdc.gov/coca/ppt/2013/06_13_13_MERSCoV_FINAL.pdf

  • SARS: Epidemiology

    • Incubation period 2–10d (median 4d) • Droplet transmission

    – Aerosol spread? – Fomites? – Fecal-respiratory transmission at an apartment

    complex in Hong Kong • Transmission most likely during 2nd week of

    illness • Super spreading events

    http://www.bt.cdc.gov/coca/ppt/2013/06_13_13_MERSCoV_FINAL.pdf

  • Middle East Respiratory Syndrome

    Images: www.cdc.gov

  • Case #1: June 13, 2012 • 60 year-old man from Saudi Arabia • 7 days of fever, cough, shortness of breath

    Hospital Day 1 Hospital Day 3

    N Engl J Med 367;19, Nov 2012

  • Case #2: September 9, 2012

    • 49 year-old man from Qatar – Recent travel to Saudi Arabia – History of farm (camels and sheep) exposure

    • 6 days of cough, myalgia and arthralgia • Admitted to Qatari hospital with bilateral

    pneumonia • Transferred to London for respiratory and

    renal failure

    Eurosurveillance, Vol. 17:40, Oct. 4, 2012

  • MERS-CoV: Identification

    • Viruses from cases 1 and 2 99.5% identical

  • MERS-CoV: Background

    • First identified in September, 2012

    • Cases retrospectively identified as early as March 2012

    • Different from other coronaviruses in humans, including SARS

    • Most similar to coronaviruses found in bats

  • MERS-CoV: Origins

    • Several studies have identified MERS-CoV in high proportion of camels – Likely reservoir

    • Identical gene segment found in one bat

    • Mode of transmission unclear – Respiratory? Foodborne? – Few primary cases with direct

    camel contact

  • MERS-CoV Identification in Camels

    http://wwwnc.cdc.gov/eid/article/20/8/14-0590-f2.htm

  • MERS-CoV: Clinical • Range of presentations*

    – 62% severe respiratory illness – 5% mild symptoms – 21% asymptomatic

    • Data from early cases – High mortality – Lower respiratory tract illness, fever

    • Data from more recent cases – Lower mortality – Higher proportion with upper respiratory tract illness

    • No vaccine, no specific treatment

    Cases with available data through 5/9/14; WHO

    PresenterPresentation Notes62% of cases involved severe respiratory illness requiring hospitalization, 32 (5%) occurred in persons who had mild symptoms or illness not requiring hospitalization and 110 (21%) were asymptomatic

  • MERS-CoV: Epidemiology

    • Case demographics – 65% male – Median age 49 years (9 months–94 years)

    • Incubation period 2–14 days • Infectious period

    – Under investigation – Not believed contagious before onset

  • MERS CoV: Transmission

    • ~75% identified as “secondary” – Mostly healthcare workers (19% of all cases) – Many with no or minor symptoms

    • Many clusters identified – Healthcare – Household (estimated 1.3% secondary attack rate)

    • No sustained person-to-person transmission

  • • 614 cases* – 181 deaths (29%)

    • Majority of case in Saudi Arabia

    • Other affected countries – United Arab Emirates, Qatar, Oman, Jordan,

    Kuwait, Yemen, Lebanon – UK, France, Turkey, Tunisia, Italy, Greece, Malaysia,

    USA, Egypt, Netherlands

    MERS Co-V: Current Status*

    *WHO, May 19, 2014

  • MERS-CoV Cases by Country of Presumed Exposure

  • MERS-CoV Cases by Country of Residence

    http://www.cdc.gov/mmwr/preview/mmwrhtml/mm63e0514a1.htm

  • Source: WHO

    MERS-CoV: Epidemic Curve

  • MERS-CoV Cases by Case Type

  • MERS in the United States

    • First case confirmed May 2, 2014 – HCW from Saudi Arabia – Diagnosed and hospitalized in Indiana

    • Second case confirmed May 11, 2014 – HCW from Saudi Arabia – Diagnosed and hospitalized in Florida

  • Volume of Travelers from Saudi Arabia and the United Arab Emirates, April-May, 2014

    PresenterPresentation NotesFive cities in the United States accounted for 75% of arrivals from Saudi Arabia and UAE; approximately 100,000 travelers are estimated to arrive in these five cities from Saudi Arabia and UAE in May and June 2014.

  • MERS-CoV: Public Health Actions

    Contact Epi On-Call immediately for any patient in whom MERS is considered

  • Patient Under Investigation: A • Fever and pneumonia or acute respiratory distress

    syndrome

    AND EITHER

    • Travel from affected region within 14 days before symptom onset

    OR

    • Close contact with a symptomatic traveler

    OR

    • Member of a cluster of patients with severe acute respiratory illness of unknown etiology in which MERS-CoV is being evaluated

  • Patient Under Investigation: B

    • Close contact with a confirmed or probable case of MERS while the case was ill

    AND

    • Fever (>100°F) or symptoms of respiratory

    illness within 14 days following the close contact. (lower threshold than category A.)

  • MERS-CoV: Close Contact Definition

    • Provided care for a MERS patient – Healthcare worker – Family member – Similarly close physical contact

    • Stayed at same place (e.g. lived with, visited)

    as MERS patient while the patient was ill

  • MERS-CoV: Testing

    • Available at SLPH with prior approval • Guidance available on DPH website

  • MERS-CoV: Infection Control

    • Healthcare settings – Contact, droplet and airborne isolation

    • Fit-tested N95 or higher level respirators • Gowns, gloves and eye protection • Negative-pressure airborne infection isolation

    – Surgical mask when out of room • Home

    – Follow guidance for ill persons, care givers and close contacts

    http://www.cdc.gov/coronavirus/mers/infection-prevention-control.html

  • MERS: Isolation and Quarantine

    • Recommendations evolving – Voluntary home quarantine used for close contacts to

    IN and FL cases – Other contacts asked to self-monitor if asymptomatic

    • Based on degree of risk

    – Higher risk: Household contact and HCWs with unprotected exposures

    – Lower risk: Travel contacts, ED patient contacts, community contacts

  • CDC Travel Alert Level 2

    • Travelers going to provide health care services are advised to practice CDC’s recommendations for infection control of confirmed or suspected cases and to monitor their health closely

    • Travelers who are going for other reasons are advised to follow standard precautions, such as hand washing and avoiding contact with people who are ill

  • Summary

    • New virus with high case-fatality rate • Spreads person-to-person but no sustained

    transmission • Rapid increase in number of cases during

    Spring 2014 – First US cases identified May 2014

    • Need for provider and public education to increase chances of early detection

  • Middle East Respiratory Syndrome Coronavirus �(MERS-CoV)Coronaviruses (CoVs) Non-SARS Human CoVs: EpidemiologyNon-SARS Human CoVs:�Clinical Spectrum of IllnessSARSSARS: EpidemiologyMiddle East Respiratory SyndromeCase #1: June 13, 2012Case #2: September 9, 2012MERS-CoV: IdentificationMERS-CoV: BackgroundMERS-CoV: OriginsMERS-CoV Identification in CamelsMERS-CoV: Clinical MERS-CoV: EpidemiologyMERS CoV: TransmissionMERS Co-V: Current Status*MERS‐CoV Cases by Country of �Presumed ExposureMERS‐CoV Cases by Country of �ResidenceMERS-CoV: Epidemic CurveMERS-CoV Cases by Case TypeMERS in the United StatesVolume of Travelers from Saudi Arabia and the United Arab Emirates, April-May, 2014MERS-CoV: Public Health ActionsPatient Under Investigation: APatient Under Investigation: BMERS-CoV: Close Contact Definition MERS-CoV: Testing MERS-CoV: Infection ControlMERS: Isolation and QuarantineCDC Travel Alert Level 2 SummarySlide Number 33